Vertex Pharmaceuticals had its Relative Strength (RS) Rating upgraded from 70 to 73 Tuesday — a welcome improvement, but still shy of the 80 or better score you look for.
This unique rating identifies market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research reveals that the best-performing stocks typically have an RS Rating of at least 80 as they launch their biggest runs. See if Vertex Pharmaceuticals can continue to rebound and hit that benchmark.
How To Invest In Stocks In Both Bull And Bear Markets
Vertex Pharmaceuticals is trying to complete a consolidation with a 519.88 entry. See if it can clear the breakout price in heavy trade.
While EPS growth dropped in the company's most recent quarterly report from 7% to -5%, sales grew 16%, up from 12% in the prior report.
The company earns the No. 4 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
